clinical trial · NCT04572893
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
Bristol-Myers Squibb·phase2·terminated·n = 41
Primary Familial Dilated Cardiomyopathydanicamtiv
brief summary
The purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities.
started
Aug 4, 2020
primary completion
Feb 22, 2024
completion
Feb 22, 2024
last updated
May 21, 2025
official title
An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants With Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other Causalities
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol